Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quisqualic acid is a naturally occurring amino acid and potent agonist of several glutamate receptor subtypes. It acts as an agonist at ionotropic glutamate receptors—specifically AMPA and kainate receptors—as well as group I metabotropic glutamate receptors (mGluR1 and mGluR5). By binding to these receptors in the central nervous system, quisqualic acid induces excitatory neurotransmission through increased sodium and calcium influx into neurons. Overactivation can lead to excitotoxicity and neuronal damage. The compound is derived from the seeds and fruit of *Quisqualis chinensis* and is primarily used experimentally in neuroscience research to study excitatory amino acid receptor function[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quisqualic acid.